Tag Archives: Takeda

Poseida, Caribou, and Takeda Presented Data for Hematological Malignancies; AACR 2024 Analysis 2

AACR 2024 Analysis 2: Poseida, Caribou, and Takeda presented clinical and preclinical updates from their programs in hematological malignancies. Below, Celltelligence provides insights and key context for selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Cellpoint (Galapagos) and Takeda Present Novel CAR-Ts for Hematological Tumors; EBMT – EHA CAR-T Meeting 2023 Analysis 1

EBMT – EHA CAR-T Meeting 2023 Analysis 1: Cellpoint (Galapagos) and Takeda presented initial clinical and preclinical data from their CAR-T therapies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ICT, Takeda, and PACT Pharma Report Clinical Data in Solid Tumors; SITC 2022 Final Analysis

SITC 2022 Final Analysis: Innovative Cellular Therapeutics (ICT), Takeda, and PACT Pharma presented clinical results from their T cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Takeda to Acquire GammaDelta Tx; Will Gilead (Kite) Pursue Gadeta?

On Wednesday, October 27, Takeda announced (press release) that they aim to fully acquire GammaDelta Therapeutics during Q1 2022 of Takeda’s fiscal year. Below, Celltelligence provides insights on why Takeda’s acquisition of GammaDelta Tx makes sense, while discussing whether Gilead (Kite) could prioritize acquiring Gadeta.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts On the Evolution of the Cell Therapy Landscape; Will Traditional αβ CAR-T Cells be Replaced by Novel Cell Types?

Although cell therapy companies have traditionally used alpha beta (αβ) T cells to manufacture CAR-T therapies, the cell therapy field is rapidly evolving with an increasing number of companies developing novel and highly differentiated platforms. Below, Celltelligence discusses how CAR-derived therapies from natural killer (NK) cells, gamma delta (γδ) T cells, macrophages, and iPSCs could treat liquid or solid tumors and whether these novel cell types may overcome the challenges and limitations faced by conventional CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Spotlight on Bayer’s and Takeda’s Cell Therapy Strategy Part 2

In our part 1 Spotlight blast, Celltelligence discussed Bayer’s expanding position within the cell therapy space (see previous insight). Below, Celltelligence continues our analysis with an overview of Takeda’s approach while performing a head-to-head comparison of Bayer and Takeda in the cell therapy space.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Spotlight on Bayer’s and Takeda’s Cell Therapy Strategy Part I

As Bayer continues to invest and expand into the cell therapy space, the Celltelligence team provides an analysis below on Bayer’s possible strategy, manufacturing technology, and partnerships. In a subsequent part 2 blast, the Celltelligence team will provide a similar overview for Takeda, who appears to be pursuing a similar cell therapy approach.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.